IQ EQ FUND MANAGEMENT IRELAND Ltd Raises Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 143.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 200,470 shares of the company's stock after purchasing an additional 118,118 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.05% of Recursion Pharmaceuticals worth $1,355,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in RXRX. Victory Capital Management Inc. raised its position in shares of Recursion Pharmaceuticals by 25.1% in the 3rd quarter. Victory Capital Management Inc. now owns 27,394 shares of the company's stock valued at $181,000 after purchasing an additional 5,503 shares during the last quarter. Intech Investment Management LLC acquired a new position in Recursion Pharmaceuticals during the 3rd quarter valued at approximately $349,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Recursion Pharmaceuticals by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock worth $12,789,000 after buying an additional 288,926 shares during the last quarter. Centaurus Financial Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the third quarter worth $71,000. Finally, Qsemble Capital Management LP purchased a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at $224,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Remove Ads

Analyst Ratings Changes

RXRX has been the subject of a number of research reports. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners cut their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Finally, Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $8.25.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX traded down $0.49 during mid-day trading on Monday, reaching $5.32. The company had a trading volume of 14,044,755 shares, compared to its average volume of 10,768,029. The stock has a market capitalization of $2.14 billion, a P/E ratio of -3.48 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.20 and a 52-week high of $12.36. The stock has a 50 day moving average of $7.44 and a two-hundred day moving average of $7.01. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. During the same period in the previous year, the business earned ($0.42) EPS. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. On average, analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.